Stimufend (PEGfilgrastim-Fpgk) Patent Expiration, LOE Window & CMS Spending

Stimufend (PEGfilgrastim-Fpgk) by Fresenius Kabi: Biologic BLA (Purple Book Regime), 0 AB generics, $9.0M 2024 CMS Part D & Medicaid spend, and $4,175 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayB761173 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$9.0M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$9.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($4,175 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.